Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study

Aimi, Fabio; Procopio, Maria-Giuseppina; Flores, Maria Teresa Alvarez; Brouland, Jean‐Philippe; Piazzon, Nathalie; Brajkovic, Saška; Dupouy, Diego; Gijs, Martin A. M.; Leval, Laurence de

doi:10.1007/s00428-019-02616-7

Cited by 8 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(b) performing anticancer drug screening [61][62][63]. (c) setting-up or improving diagnosis or prognosis applications such as the detection and isolation of circulating tumor cells (CTCs) [64][65][66], the analysis of tumor cell exosomes or nucleic acids [67] and the rapid performing of immunohistochemistry staining protocols [68].…”

Section: Microfluidics Applications For Studying Cancer: Coc Conceptmentioning

confidence: 99%

Cancer-on-chip technology: current applications in major cancer types, challenges and future prospects

et al. 2022

View full text Add to dashboard Cite

Conventional 2D cell cultures are widely used for the development of new anticancer drugs. However, their relevance as in vitro models is increasingly questioned as they are considered too simplistic compared to complex, three-dimensional in vivo tumors. Moreover, animal experiments are not only costly and time-consuming, but also raise ethical issues and their use for some applications has been restricted. Therefore, it becomes crucial to develop new experimental models that better capture the complexity and dynamic aspects of in vivo tumors. New approaches based on microfluidic technology are promising. This technology has indeed been used to create microphysiological systems called ‘organ-on-chip’ which simulate key structural and functional features of human tissues and organs. These devices have further been adapted to create cancer models giving rise to the ‘cancer-on-chip’ (COC) concept. In this review, we will discuss the main COC models described so far for major cancer types including lung, prostate, breast, colorectal, pancreatic, and ovarian cancers. Then, we will highlight the challenges that this technology is facing and the possible research perspectives that can arise from them.

show abstract

Section: Microfluidics Applications For Studying Cancer: Coc Conceptmentioning

confidence: 99%

Cancer-on-chip technology: current applications in major cancer types, challenges and future prospects

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Annually, there is a continued increase in the number of reports of tumor-on-chip devices, an extensive overview of which is available by Li et al (2018) . Microfluidic chips have been applied in BC diagnostics for quick and standardized detection of specific biomarkers like: ER, PR, HER2, and Ki67 (proliferation marker) on fixed tissue samples ( Cho et al, 2018 ; Aimi et al, 2019 ), and for early detection of circulating cancer cells ( Fang et al, 2017 ). Microfluidic diagnostics and novel 3D models provide insight into the physiology of patient-specific BCs, open the door to precision medicine, and have already been used to test new and alternative treatments for BCs ( Cho et al, 2018 ).…”

Section: Toward Tissue-specific Breast Cancer Modelsmentioning

confidence: 99%

Engineering Breast Cancer On-chip—Moving Toward Subtype Specific Models

Moccia

Haase

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Breast cancer is the second leading cause of death among women worldwide, and while hormone receptor positive subtypes have a clear and effective treatment strategy, other subtypes, such as triple negative breast cancers, do not. Development of new drugs, antibodies, or immune targets requires significant re-consideration of current preclinical models, which frequently fail to mimic the nuances of patient-specific breast cancer subtypes. Each subtype, together with the expression of different markers, genetic and epigenetic profiles, presents a unique tumor microenvironment, which promotes tumor development and progression. For this reason, personalized treatments targeting components of the tumor microenvironment have been proposed to mitigate breast cancer progression, particularly for aggressive triple negative subtypes. To-date, animal models remain the gold standard for examining new therapeutic targets; however, there is room for in vitro tools to bridge the biological gap with humans. Tumor-on-chip technologies allow for precise control and examination of the tumor microenvironment and may add to the toolbox of current preclinical models. These new models include key aspects of the tumor microenvironment (stroma, vasculature and immune cells) which have been employed to understand metastases, multi-organ interactions, and, importantly, to evaluate drug efficacy and toxicity in humanized physiologic systems. This review provides insight into advanced in vitro tumor models specific to breast cancer, and discusses their potential and limitations for use as future preclinical patient-specific tools.

show abstract

“…More importantly, microfluidic chips need a shorter detection time than conventional medical detection devices; thus, microfluidic chips are particularly suitable for rapid detection in areas with scarce medical resources. Microfluidic technologies have been used in fields including medical diagnosis [9], laboratory testing [10,11], cell analysis [12], and other biochemical research because of their convenient operation, small size, and portability. Microfluidic technology has also enabled the development of point-of-care (POC) technologies.…”

Section: Introductionmentioning

confidence: 99%

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Yang

Zhang

et al. 2022

Sensors

129

View full text Add to dashboard Cite

The early diagnosis of infectious diseases is critical because it can greatly increase recovery rates and prevent the spread of diseases such as COVID-19; however, in many areas with insufficient medical facilities, the timely detection of diseases is challenging. Conventional medical testing methods require specialized laboratory equipment and well-trained operators, limiting the applicability of these tests. Microfluidic point-of-care (POC) equipment can rapidly detect diseases at low cost. This technology could be used to detect diseases in underdeveloped areas to reduce the effects of disease and improve quality of life in these areas. This review details microfluidic POC equipment and its applications. First, the concept of microfluidic POC devices is discussed. We then describe applications of microfluidic POC devices for infectious diseases, cardiovascular diseases, tumors (cancer), and chronic diseases, and discuss the future incorporation of microfluidic POC devices into applications such as wearable devices and telemedicine. Finally, the review concludes by analyzing the present state of the microfluidic field, and suggestions are made. This review is intended to call attention to the status of disease treatment in underdeveloped areas and to encourage the researchers of microfluidics to develop standards for these devices.

show abstract

Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study

Cited by 8 publications

References 20 publications

Cancer-on-chip technology: current applications in major cancer types, challenges and future prospects

Cancer-on-chip technology: current applications in major cancer types, challenges and future prospects

Engineering Breast Cancer On-chip—Moving Toward Subtype Specific Models

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Contact Info

Product

Resources

About